The Benderson family of Sarasota, Florida, donated $5 million to the Dana-Farber Cancer Institute in Boston, MA, representing the largest philanthropic gift addressing triple-negative breast cancer research (TNBC) and care in the history of the research...
Breast Cancer
Category
Machine Learning Being Used to Analyze the Interaction of Breast Cancer Risk Factors
A new innovative use of machine learning to help understand the interplay of genetic and other breast cancer risk factors has been reported in a recently published article from University of Eastern Finland and Kuopio University Hospital. Approaches capable of merging...
Dartmouth & Partner Receive $3m NCI Grant for New Breast Tumor Diagnostic Technology
An Academic-Industry Partnership (AIP) led by Dartmouth researchers received a $3 million grant from the National Cancer Institute to develop a superior breast diagnostic technology. More specifically, the team seeks to pursue the idea of developing a multi-model...
ChristianaCare Study Discovers Radiation-triggered Inflammation can Drive Triple-Negative Breast Cancer
A study led by an investigator with ChristianaCare’s Helen F. Graham Cancer Center & Research Institute concludes that the radiation used to treat breast cancer by killing cancer cells can cause side effects, including inflammation, which in turn can introduce a...
THE WISDOM Study Assesses Annual Mammogram vs. Personalized Screening Program
The WISDOM study represents a groundbreaking effort to determine the optimal guidelines for breast cancer screening and now seeks qualifying women across the country that would like to contribute to improving breast cancer screening and prevention. WISDOM was recently...
UT Southwestern Leads Study Demonstrating Neratinib & Everolimus Combo Halts Growth of Cancer Cells with HER2 Mutations
UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combination that halts the growth of cancer cells that carry HER2 mutations. Patients with cancers harboring HER2 mutations eventually develop resistance to a promising new cancer drug...
Government-Insured Patients At Greater Risk with Breast Cancer According to New ECOG-ACRIN Study
Medicaid and Medicare beneficiaries are more likely to die from breast cancer or stop treatment early than those women who are on commercial insurance based on the results of a study of 10,000 women presented on December 12, at the San Antonio Breast Cancer...
A Life Saved by City of Hope Clinical Trial: Why aren’t more Cancer Patients Enrolling in Clinical Trials?
Laura Holmes Haddad was diagnosed with Stage IV inflammatory breast cancer at 37—the mom of two children ages 1 and 4. A rare and aggressive form of cancer attacking the lymphatic system near the breast, it is a deadly form of the disease—typically far distributed...
SWOG Cancer Research Network Study Confirms New Prognostic Markers for Triple Negative Breast Cancer
Investigators from SWOG Cancer Research Network have confirmed research findings published in the Journal of Clinical Oncology that two biomarkers—a 44-gene DNA Damage Response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs)—can serve as prognostic...
Metastatic Breast Cancer Alliance Announces Breast Cancer Patient and Researcher Engagement & Matching Tool
The Metastatic Breast Cancer Alliance (MBCA), the largest coalition of nonprofit breast cancer organizations, pharmaceutical/biotech companies, and patient advocates in America, released MBC Connect 2.0, an interactive web-and-mobile-friendly patient registry...
West Cancer Center Investigators Discuss Ongoing Breast Cancer Clinical Trials
West Cancer Center breast cancer experts recently discussed promising research being conducted at their research center. Based in Tennessee, West Cancer Center is the region’s comprehensive leader in adult cancer research, delivering a complete continuum of care to...
Noguchi Memorial Institute Studies the Plant World to Find Modern Anti-Cancer Fighting Compounds
Noguchi Memorial Institute for Medical Research has participated in some compelling cancer research since its inception in 1979. With an interest in understanding local herbal medicine and how it can augment and contribute to more advanced “Western” medicines, they...
Chinese Biotech’s Herceptin Biosimilar Meets Endpoint & Moves Closer to Approval
Shanghai Henlius Biotech’s HLX02, a trastuzumab biosimilar, achieved similar overall response rates (ORR) to reference trastuzumab (Herceptin®; Roche) in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic...
University of Florence & ICR London Discover Change in Cell Logistics Helps Breast Cancer to Become Resistant to Hormone Therapy
The University of Florence researchers, in collaboration with London’s Institute of Cancer Research, have uncovered a potential cause of sustained resistance to hormone therapy in the most common form of breast cancer. The findings could help us someday find new...
New Research Suggests Effectiveness of Simple Blood Test for Early Detection of Breast Cancer
Breast cancer could be detected up to five years before there are any clinical signs of it, using a blood test that identifies the body's immune response to substances produced by tumour cells, according to new research presented at the 2019 NCRI Cancer Conference...
Seattle Genetics Reports Positive Topline Results from HER2CLIMB Trial of Tucatinib in HER2+ Breast Cancer
Seattle Genetics announced positive topline results from the HER2CLIMB trial, which compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive...
The “Triple Whammy of Barriers” Breast Cancer Patients Face in Kenya
Any mention of cancer in Kenya today elicits fear and trepidation. It is discussed in hushed tones from church pulpits to Parliament and slums, and villages to presidential events. It has reached catastrophic levels akin to terror attacks at the turn of this decade or...
UCLA’s Dr. Dennis J. Slamon & Patient Discuss the Results of MONALEESA-3 (Novartis) and Potential for Metastatic Breast Cancer Patients
An investigational breast cancer drug shows promise with the recent MONALEESA-3 results. Overall survival data in women with HR+/HER2-metastatic breast cancer according to recent presentations at the Presidential Symposium at the European Society for Medical Oncology...
Personalised Breast Cancer Programme (PBCP) in UK Using Gene Analysis to Potentially Guide Treatment Decisions
Dr Jean Abraham co-leads the Personalised Breast Cancer Programme (PBCP), a collaboration between Cancer Research UK and Addenbrooke’s Charitable Trust. It has analysed the genes of 600 breast cancer patients to see if they could do this quickly enough to use the...
One of America’s Greatest Breast Cancer Investigators Dies at 101
The University of Pittsburgh’s Dr. Bernard Fisher, a surgeon whose research led to a transformation for how breast cancer would be treated, ending the routine use of debilitating radical mastectomy, died this past Wednesday. He was 101. Dr. Fisher conducted many...